McNicoll

McNicoll, Lewis & Vlak downgraded Genomic Health (NASDAQ: GHDX) from Buy to Hold in a research report published today. McNicoll, Lewis & Vlak has a $30 price target on the company. In the report, McNicoll, Lewis & Vlak states, "Genomic Health will launch of a new subsidiary to...

McNicoll, Lewis & Vlak reaffirmed its Transcept Pharmaceuticals (NASDAQ: TSPT) Buy rating and $21 price target in a research report published today.

McNicoll, Lewis & Vlak maintained its Keryx Biopharmaceuticals (NASDAQ: KERX) Buy rating and $18 price target in a research report published today. In the report, McNicoll, Lewis & Vlak states, "In our view, Keryx's clinical trials are progressing well while the company maintains a firm...

McNicoll, Lewis & Vlak maintained its Royal Gold (NASDAQ: RGLD) Buy rating and $97.70 price target in a research report published today.

McNicoll, Lewis & Vlak reiterated its Affymax (NASDAQ: AFFY) Buy rating and $12 price target in a research report published today. Shares of Affymax were trading at $5.35 at the time of posting, up 4.70% from Friday's market close.

McNicoll, Lewis & Vlak reiterated its Ligand Pharmaceuticals (NASDAQ: LGND) Buy rating and $30 price target in a research report published today. In the report, McNicoll, Lewis & Vlak states, "With 8 marketed drugs and more than 50 fully funded programs, we view LGND as a more de-risked...

McNicoll, Lewis & Vlak maintained its Spectrum Pharmaceuticals (NASDAQ: SPPI) Buy rating and $20.50 price target in a research report published today. In the report, McNicoll, Lewis & Vlak states, " This morning, before markets opened, Spectrum Pharmaceuticals, Inc. (SPPI; Last close: $8....

McNicoll, Lewis & Vlak maintained its Aastrom Biosciences (NASDAQ: ASTM) Buy rating and $7.50 price target in a research report published today. In the report, McNicoll, Lewis & Vlak states, " This morning at the annual meeting of the 15th Annual Heart Failure Society of America Scientific...

McNicoll, Lewis & Vlak reiterated its Vivus (NASDAQ: VVUS) Buy rating and $16 price target in a research report published today. In the report, McNicoll, Lewis & Vlak states, " Today, VVUS announced data from the 47th European Association for the Study of Diabetes (EASD), which highlighted...

McNicoll, Lewis & Vlak maintained its Peregrine Pharmaceuticals (NASDAQ: PPHM) Buy rating and $8.50 price target in a research report published today. In the report, McNicoll, Lewis & Vlak states, "This morning, before the markets opened, Peregrine Pharmaceuticals, Inc. (PPHM; Last close...

McNicoll, Lewis & Vlak maintained its Keryx Biopharmaceuticals (NASDAQ: KERX) Buy rating and $18 price target in a research report published today. In the report, McNicoll, Lewis & Vlak states, "Based on positive efficacy and safety results of a small, 35-patient, randomized, double-blind...

McNicoll, Lewis & Vlak maintained its Aeterna Zentaris (NASDAQ: AEZS) Buy rating and $5.50 price target in a research report published today. In the report, McNicoll, Lewis & Vlak states, "This morning, Æterna Zentaris (AEZS; Last close: $1.89) announced positive top-line results of its...

McNicoll, Lewis & Vlak maintained its Peregrine Pharmaceuticals (NASDAQ: PPHM) Buy rating and $8.50 price target in a research report published today. In the report, McNicoll, Lewis & Vlak states, "Currently, Peregrine is conducting three randomized Phase II trials of Bavi in combination...

McNicoll, Lewis & Vlak downgraded its Transcept Pharmaceuticals (NASDAQ: TSPT) rating from Buy to Hold and lowered its Transcept Pharmaceuticals price target from $15 to $5.50 in a research report published today. In the report, McNicoll, Lewis & Vlak states, "Due to the clear uncertainty...

McNicoll, Lewis & Vlak reiterated its Affymax (NASDAQ: AFFY) Buy rating and $12 price target in a research report published today. In the report, McNicoll, Lewis & Vlak states, "AFFY ended 2Q:11 with $73.6M in cash and equivalents, and $39.7M in short term investments. Based on the 2011...